We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The treatment of multiple sclerosis, with the first treatments that appeared at the beginning of the 1990s, has allowed the natural history of the disease to change. The proportion of disabled people is getting smaller and smaller. However, there is a long way to go when it comes to treating the clinical presentation and progressive physiopathology that can be related to the disease.
At present, the challenge is to offer the appropriate drug for patients, i.e. ‘personalised’ or ‘precision medicine.’ It is also key to quickly detect patients who do not respond to a specific treatment. This is why there are different ways of addressing the disease.
Primary treatment line or moderate efficacy treatments:
These types of treatment are indicated in patients with low inflammatory load, in whom it is expected to control inflammation with drugs of moderate effectiveness. These are drugs that have an acceptable safety profile, with adverse effects that are usually mild. Deciding between different front-line drugs depends on the method of administration, the profile of adverse effects, gestational desire or the patient’s medical history. You can find:
Second line of treatment or highly effective treatment:
In this case, treatments are indicated in patients with high inflammatory load or persistent inflammation, despite moderate treatment. These are drugs that can potentially cause adverse effects such as systemic or central nervous system infections. The choice of drugs is based on the safety profile, gestational desire, pathological history and degree of inflammation of patients. The most common are:
Treatment due to progression with inflammatory activity:
There are two specific medications: ocrelizumab is used in patients with progressive multiple sclerosis, the only progressively available treatment, while siponimod is used in patients with progression after a remission-recurring phase.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.